Tofacitinib in Juvenile Idiopathic Arthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study uses real-world clinical practice data to examine the effectiveness of tofacitinib for pediatric JIA. Participants are patients under 18 who have been treated with tofacitinib and have a documented JIA diagnosis and treatment indication. The analysis focuses on clinical control after 12 months of therapy, reflecting routine care settings rather than a controlled trial. Exclusion criteria include arthritis related to inflammatory bowel disease or other autoimmune conditions. The study is conducted at multiple hospitals in Spain, with the lead sponsor Consorci Sanitari de l'Alt Penedès i Garraf.

Why it matters

Who can join: the full rules

Inclusion criteria:

Diagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist.

Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA.

Age under 18 years at the time of the treatment indication with tofacitinib.

Exclusion criteria:

Participants diagnosed with any of the following conditions:

Reactive arthritis

Arthritis associated with inflammatory bowel disease

Arthritis associated with another autoimmune disease

Where it's running

• Hospital Universitario de A Coruña
  A Coruña, A Coruña, Spain Recruiting
• Hospital Universitari Germans Trias i Pujol
  Badalona, Barcelona, Spain Recruiting
• Hospital Sant Joan de Déu Barcelona
  Barcelona, Barcelona, Spain Recruiting
• Althaia Xarxa Assistencial Universitaria de Manresa
  Manresa, Barcelona, Spain Recruiting
• Corporació Sanitària Parc Taulí de Sabadell
  Sabadell, Barcelona, Spain Recruiting
• Hospital de Vilafranca
  Vilafranca del Penedès, Barceona, Spain Recruiting

Study contacts

• Study coordinator: Noemí Casaponsa
• Email: recerca@csapg.cat
• Phone: +34938960025

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

• Predicting the course of early-onset juvenile idiopathic arthritis using a multidimensional model

  Researchers are testing a comprehensive model to predict how early-onset JIA will progress in affected children and how a small control group with iridocyclitis compares.

  Recruiting at 2 sites Istituto Giannina Gaslini · Genova and 1 other locations · NCT07882667

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

• Understanding subtypes of chronic musculoskeletal pain in youth

  This observational study tests whether distinct brain and immune profiles can explain chronic musculoskeletal pain in teens and young adults to guide more precise treatments.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07602595

• Heart event risk in people with moderate-to-severe rheumatoid arthritis taking tofacitinib plus a statin versus TNF inhibitors.

  This will test whether taking tofacitinib with a daily statin changes the rate of major heart problems in people 50 and older with moderate-to-severe rheumatoid arthritis and at least one cardiovascular risk factor.

  Recruiting Phase 4 Shaikh Zayed Hospital, Lahore · Lahore, Punjab Province · NCT07554820

• Open-label extension with filgotinib for juvenile idiopathic arthritis

  This long-term open-label extension sees if filgotinib stays safe and continues to control symptoms in children aged 8–17 with polyarticular or systemic juvenile idiopathic arthritis who benefited from earlier treatment.

  Recruiting at 2 sites Phase 3 Alfasigma S.p.A. · Le Kremlin-Bicêtre and 3 other locations · NCT07553182

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.